D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2297-2301

  Knudsen, Karen E ^a,b   Cavenee, Webster K ^a   Arden, Karen C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; COMPLEX FORMATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOSIS; PLASMID; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SYNTHESIS; TRANSACTIVATION; TRANSCRIPTION REGULATION;

CELL CYCLE; CYCLIN D1; CYCLINS; FEEDBACK; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ANDROGEN; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0033563091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
2. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347, 1997.
3. Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., and Michalides, R. J. A. M. CDK-independent activation of estrogen receptor by cyclin D1. Cell, 88: 405-415, 1997.
4. Inoue, K., and Sherr, C. J. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent kinase independent mechanism. Mol. Cell. Biol., 18: 1590-1600, 1998.
5. Palmero, I., and Peters, G. Perturbation of cell cycle regulators in human cancer. Cancer Surv., 27: 351-367, 1996.
6. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol., 14: 1669-1679, 1994.
7. Montie, J. E., and Pienta, K. J. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 43: 892-899, 1994.
8. Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate, 5: 545-557, 1984.
9. Trapman, J., and Brinkmann, A. O. The androgen receptor in prostate cancer. Pathol. Res Pract., 192: 752-760, 1996.
10. Pettaway, C. A. Prognostic markers in clinically localized prostate cancer. Tech. Urol., 4: 35-42, 1998.
11. 1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem., 273; 20213-20222, 1998.
12. Chen, C., and Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987.
13. Cleutjens, K. B. J. M., van der Korput, H. A. G. M., van Eekelen, C. C. E. M., van Rooij, H. C. J., Faber, P. W., and Trapman, J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate specific antigen promoter. Mol. Endocrinol., 11: 148-161, 1997.
14. Palvimo, J. J., Ksllio, P. J., Ikonen, T., Mehto, M., and Janne, O. A. Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Mol. Endocrinol., 93: 1399-1407, 1993.
15. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
16. Templeton, D. J., Park, S. H., Lanier, L., and Weinberg, R. A. Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. Proc. Natl. Acad. Sci. USA, 88: 3033-3037, 1991.
17. Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., and Weinberg, R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73: 499-511, 1993.
18. Ikonen, T., Palvimo, J. J., and Janne, O. A. Interaction between the ammo- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor co-activators. J. Biol. Chem., 272: 29821-29828, 1997.
19. Kimmick, G. G., and Muss, H. B. Endocrine therapy in metastatic breast cancer. Cancer Treat. Res., 94: 231-254, 1998.
20. Bartkova, J., Lukas, J., Meuller, H., Leutzhft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
21. Sonnenschein, C., Olea, N., Pasanen, M. E., and Soto, A. M. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res., 49: 3474-3481, 1989.
22. Sellers, W. R., and Kaelin, W. G., Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol., 15: 3301-3312, 1997.
23. 1/S-regulating genes in human cancer. Prog. Cell Cycle Res., 3: 211-220, 1997.
24. Gumbiner, L. M., Gumerlock, P. H., Mack, P. C., Chi, S-G., deVere White, R. W., Mohler, J. L., Pretlow, T. G., and Tricoli, J. V. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate, 38: 40-45, 1999.
25. Phillips, S. M., Barton, C. M., Lee, S. J., Morton, D. G., Wallace, D. M., Lemoine, N. R., and Neoptolemos, J. P. Loss of the retinoblastoma susceptibility gene RB1 is a frequent and early event in prostatic tumorigenesis. Br. J. Cancer, 70: 1252-1257, 1994.